BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech) 
 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BCMA-targeted Prime CAR-T cells (Chongqin
 g Precision Biotech)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04776330-3425@assetmemo.bio
DTSTAMP:20261121T011244Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech): Phas
 e 1/2 readout est. (NCT04776330)
DESCRIPTION:BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)\,
  phase 1/2\, Multiple Myeloma.\nStudy: a Clinical Research of BCMA-Targete
 d Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Pla
 sma Cell Disease\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bcma-targeted-prime-car-t-cel
 ls-chongqing-precision-biotech#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04776330
URL:https://assetmemo.bio/drug/bcma-targeted-prime-car-t-cells-chongqing-pr
 ecision-biotech#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
